Business Context and Reporting Period
This Form 6-K filing by China SXT Pharmaceuticals, Inc. (the "Company") reports a material definitive agreement entered into on April 16, 2019. The filing discloses the terms of a private placement transaction involving senior convertible notes and warrants with unaffiliated institutional investors.
Key Financial Metrics and Transaction Terms
The filing details a complex financing structure rather than standard operating financial results. Key metrics include:
- Total Principal Raised: $15 million in aggregate principal amount of Senior Convertible Notes.
- Series A Notes: $10 million principal; unsecured.
- Series B Notes: $5 million principal; secured and subject to "Restricted Principal" provisions tied to Investor Notes.
- Consideration Received: $10 million in cash and a $5 million secured promissory note payable by the Investors to the Company (the "Investor Note").
- Warrants: Issued to purchase shares equal to 50% of the shares issuable upon conversion of the Notes. Exercise price is $8.38 per share with a five-year term.
- Interest Rate: 8% per annum, accruing monthly. Increases to 18% per annum upon an event of default.
- Maturity Date: October 2, 2020.
- Amortization: Principal repayable in 23 tri-weekly installments starting June 28, 2019. Repayment may be in cash or shares at the Company's option, subject to equity conditions.
- Conversion Price: Initial fixed price of $8.38 per share, subject to downward adjustments (ratchets) based on future issuances or market price declines.
Material Changes and Transaction Structure
The primary material change is the execution of the Securities Purchase Agreement. The transaction structure includes unique features:
- Investor Notes: Investors issued $5 million in notes to the Company at 2.55% interest, maturing in 30 years. These notes are subject to mandatory prepayment upon conversion of Series B Notes or upon the effectiveness of a registration statement for resale of shares.
- Offset Rights: Extensive offset provisions allow Investors to cancel their obligation to pay the Investor Note by cancelling an equal amount of the Series B Note principal under specific conditions (e.g., equity condition failures, events of default, or change of control).
- Security Interest: Investors hold a security interest in the Investor Notes. Additionally, Feng Zhou Management Limited pledged 4 million ordinary shares to secure the Company's obligations.
- Registration Rights: The Company must file a registration statement within 20 days and have it declared effective within 75 days (or 100 days if reviewed) to cover 200% of the shares issuable upon conversion and exercise.
- Placement Agent Fees: FT Global Capital, Inc. received a $120,000 cash fee, up to $30,000 in expense reimbursement, up to $25,000 in legal expense reimbursement, and a warrant to purchase 178,997 shares.
Guidance, Risks, and Contingencies
The filing contains significant risks and contingencies related to the financing:
- Equity Conditions: The Company's ability to repay principal in shares is contingent on meeting specific equity conditions, including maintaining a registration statement, listing on an eligible market, and meeting stock price/volume requirements. Failure to meet these conditions forces cash repayment.
- Dilution Risk: The conversion price is subject to significant downward adjustment mechanisms (ratchets) if the Company issues shares at a lower price or if the market price drops, potentially causing substantial dilution.
- Default Consequences: An event of default triggers an interest rate increase to 18%, allows holders to redeem notes at a 115% premium, and may restrict the Company's ability to force mandatory conversion.
- Liquidated Damages: The Company faces 1% liquidated damages payments every 30 days if it fails to file or maintain the effectiveness of the registration statement.
- Forward-Looking Statements: The Company notes uncertainties regarding its ability to consummate the transaction, pay interest/principal, satisfy equity conditions, and obtain necessary shareholder approvals for share issuances below the initial conversion price.
Investor Verification Checklist
- Verify the Company's current cash position and ability to meet the mandatory cash repayment requirements if equity conditions are not satisfied.
- Confirm the status of the registration statement filing required within 20 days of closing to avoid liquidated damages.
- Assess the potential dilution impact given the 50% warrant coverage and the aggressive downward ratchet provisions on the conversion price.
- Review the specific terms of the "Investor Notes" and the offset rights to understand the net cash flow implications if an event of default occurs.
- Check for any pending shareholder approvals required under Nasdaq Rule 5635(d) for issuances below the initial conversion price.